The United Kingdom and the United States have signed a landmark trade agreement that will ensure no import taxes on British medicine exports entering the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This commitment ensures that tariffs on these crucial products will remain at zero for a duration of 36 months.
This agreement comes after recent threats to dramatically increase import taxes on patented drug imports, with figures floated as high as double the cost.
"This arrangement with the UK bolsters the worldwide climate for new treatments and introduces long-overdue balance to transatlantic drug exports," an announcement noted.
Trade Impact
Medicines constitute one of the Britain's most significant export categories to the United States, which is clearly the primary destination for leading British pharmaceutical firms.
Export figures indicate that in the year prior to September, the UK sold medicines totaling billions to the US. This value represented 17.4% of British export trade in that span.
"This agreement safeguards employment, boosts funding and facilitates the UK to emerge as a worldwide center for medical research," a minister commented.
Key NHS Changes
The deal involves several key changes from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase overall public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds were more than twenty percent.
Industry Background
The deal follows a ongoing tension between the drug companies and the UK government over drug pricing and approval rates.
These tensions were intensified by assertions that US customers were charged a premium for the identical medicines than consumers in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the last ten years.
